AKT1 and breast carcinoma: Mechanistically, chemotherapeutic agents induce ACE2 expression in breast cancer cells by increasing intracellular ROS production, while increased ROS levels enhance AKT phosphorylation and subsequently upregulate HIF-1α expression.